$NWBO PATENT GRANTED THIS MORNING : 'Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers'

👋 💻🥼
Computational postdoc position in my lab ‼️
penterlab.org

Come and join me! We use cutting-edge single cell and spatial approaches to develop immunotherapeutic approaches for blood cancer.

#postdoc #position #datascience #immunotherapy #leukemia

Please RT.

🎉 Big congrats to #IrsiCaixa researcher Miguel Marin for successfully defending his PhD thesis on immunotherapeutic strategies for #HIV cure!

💪🏽 His work brings hope for a brighter future in the fight against HIV.

Targeted and Immunotherapeutic Approaches in Breast Cancers

tridhascholars.org/pdfs/targeted-…

#dcvax $nwbo #gbm

Another patent I have not seen before published November 2023. One of the longest titles I have ever seen 🤣This is from the Brazil office.

BRUS2016051781 - IN VITRO METHOD FOR DETERMINING THE IMMUNOTHERAPEUTIC POTENCE OF A COMPOSITION OF ACTIVE AND NOT

It’s finally out 🎉! Our study on how low oxygen levels sensed by CD8+ T cells during activation modulate T cell function and can be harnessed to improve immunotherapeutic efficacy eLife - the journal elifesciences.org/articles/84280. Here's the tweetorial ⬇️⬇️⬇️(1/n)

$NWBO patent granted on March 27, 2024 - IN201847013961 🇮🇳: 'Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers'

patentscope.wipo.int/search/en/deta…

“…more than 88 clinical trials on immunotherapies for GBM are being conducted worldwide…the efficacy of several immunotherapeutic treatments, including…DCVax-L and oncolytic virus (OV) has been demonstrated in phase II and III clinical trials”
$nwbo

sciencedirect.com/science/articl…

#dcvax $nwbo #gbm

A scientometric analysis of immunotherapies for gliomas: Focus on GBM
5 March 2024.

'This phase III trial paved the way for future success in the field of immunotherapy for gliomas'

'Moreover, the efficacy of several immunotherapeutic treatments, including

Chinese researchers have developed a novel immunotherapeutic agent, which can enhance T cell effector function to kill tumor cells and suppress colon tumor growth, according to a recent article in the academic journal ACS Nano.

$NWBO Patent application with completed examination - 🇮🇱 IL286225 - Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers

Next steps: Payment for acceptance fee and issuance.

patentscope.wipo.int/search/en/deta…

design principles of bioresponsive immunotherapeutic materials and discusses the critical roles of controlled release of immunoactive agents from bioresponsive materials in recruiting, housing, and manipulating immune cells for evoking desired immune responses.

Yoel Ohayon

We’ve been given the thumbs up to start recruiting patients for our #IMVAX clinical trial! 👍

This study is designed to assess progression-free survival and overall survival in newly diagnosed #Glioblastoma patients treated with a personalized cell-based immunotherapeutic

Very proud of Thomas Look @ThomasLook who obtained his PhD today after outstanding last 3.5 years, an excellent presentation and examination. Thomas worked on novel immunotherapeutic approaches against glioblastoma. More publications from this work coming soon!

Chinese researchers have developed a novel immunotherapeutic agent for treating #coloncancer , according to a recent article in the academic journal ACS Nano.

The #agent can enhance tumor immunogenicity and inhibit colon tumor growth, with no significant impact on normal cells.

$NWBO Patent granted on November 28, 2023 🇧🇷 BR112018005180 - 'Methods relating to activated dendritic cell compositions and immunotherapeutic treatments for subjects with advanced cancers'

Dr Rajiv Khanna a champion in immunotherapeutic strategies for the treatment of transplant recipients & autoimmune diseases presents 'Cellular therapies for infectious diseases' at Brisbane Transplant Infectious Diseases Meeting, 23 May. Register bit.ly/3VHXkKO

Anusha Kalbasi, MD, had his research proposal, “Immunotherapeutic targeting of fusion oncogenes in sarcoma,” selected for funding as a Stanford Cancer Institute (SCI) 2023 October Behar Innovation Award in Sarcoma Research. Congratulations, Dr. Kalbasi!

If you have a MSc and would like to do a PhD in #immunology , don't miss the opportunity to join us at @CBMSO_CSIC_UAM to work in novel immunotherapeutic strategies against #leukemia 🩸🧬💪
We're offering a 4-year predoctoral contract 📄! It could be yours 🫵!
Please, RT🔁!
⬇️⬇️⬇️

Chinese researchers develop immunotherapeutic agent for colon cancer